[go: up one dir, main page]

BG107161A - 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors - Google Patents

5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors

Info

Publication number
BG107161A
BG107161A BG107161A BG10716102A BG107161A BG 107161 A BG107161 A BG 107161A BG 107161 A BG107161 A BG 107161A BG 10716102 A BG10716102 A BG 10716102A BG 107161 A BG107161 A BG 107161A
Authority
BG
Bulgaria
Prior art keywords
so2nr4r5
compounds
hydrogen
alkylpyrido
pyrimidines
Prior art date
Application number
BG107161A
Other languages
Bulgarian (bg)
Inventor
Richard Booth
Ellen Dobrusin
Peter Toogood
Scott VANDERWEL
Original Assignee
Warner-Lambert Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company Llc filed Critical Warner-Lambert Company Llc
Publication of BG107161A publication Critical patent/BG107161A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Disclosed are compounds of the formula wherein: R2 is hydrogen, alkyl, or cycloalkyl; R3 is hydrogen, lower alkyl, lower alkoxy, halogen, trifluoromethyl, lower alkynyl, lower alkenyl, nitrile, nitro -COR4, -CO2R4, -CONR4R5, -CONR4OR5, -SO2NR4R5, -SO2NR4R5, -SO2R4, -SO3R4, formula (II) given in the description, or -NR4R5; Y is N or CR7, wherein R7 and Z can be R9 is lower alkyl, haloalkyl, or aryl, X and Z are independently hydrogen, halogen, lower alkyl, lower alkoxy, trifluoromethyl, hydroxy, nitrile, nitro, -NR4R5, -N(O)R4R5, -NR4r5R6W, -SR4, -C(O)R4, -CO2R4, -CONR4R5, -SO2NR4R5, -SO2R4, -SO3R4, P(O)(OR4)(OR5), -T(CH2)mQR4, -C(O)T(CH2)mQR4, or -NR4C(O)T(CH2)mQR5; m is 1 to 6. These compounds are useful for treating cell proliferative disorders, such as cancer, atherosclerosis, and restenosis. These compounds are potent inhibitors of cyclin-dependant kinases (cdks) and growth factor-mediated kinases. 23 claims
BG107161A 2000-03-06 2002-10-02 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors BG107161A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18712400P 2000-03-06 2000-03-06
PCT/US2001/002657 WO2001070741A1 (en) 2000-03-06 2001-01-29 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
BG107161A true BG107161A (en) 2003-06-30

Family

ID=22687699

Family Applications (1)

Application Number Title Priority Date Filing Date
BG107161A BG107161A (en) 2000-03-06 2002-10-02 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors

Country Status (36)

Country Link
EP (1) EP1268476A1 (en)
JP (1) JP2003528101A (en)
KR (1) KR20020075805A (en)
CN (1) CN1422268A (en)
AP (1) AP2002002643A0 (en)
AR (1) AR034119A1 (en)
AU (1) AU2001233028A1 (en)
BG (1) BG107161A (en)
BR (1) BR0109056A (en)
CA (1) CA2401368A1 (en)
CO (1) CO5280200A1 (en)
CR (1) CR6736A (en)
CZ (1) CZ20022929A3 (en)
DZ (1) DZ3308A1 (en)
EA (1) EA200200802A1 (en)
EE (1) EE200200506A (en)
GT (1) GT200100037A (en)
HN (1) HN2001000040A (en)
HR (1) HRP20020798A2 (en)
HU (1) HUP0300136A2 (en)
IL (1) IL151480A0 (en)
IS (1) IS6524A (en)
MA (1) MA26881A1 (en)
MX (1) MXPA02008535A (en)
NO (1) NO20024235L (en)
NZ (1) NZ520962A (en)
OA (1) OA12227A (en)
PA (1) PA8513201A1 (en)
PE (1) PE20011177A1 (en)
PL (1) PL358271A1 (en)
SK (1) SK12472002A3 (en)
SV (1) SV2001000338A (en)
TN (1) TNSN01036A1 (en)
WO (1) WO2001070741A1 (en)
YU (1) YU66502A (en)
ZA (1) ZA200207110B (en)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
CN100525768C (en) 2000-10-23 2009-08-12 史密丝克莱恩比彻姆公司 Novel compounds
CZ20032416A3 (en) * 2001-02-12 2004-07-14 F. Hoffmann-La Roche Ag 6-Substituted pyridopyrimidines
MXPA03007623A (en) 2001-02-26 2003-12-04 Tanabe Seiyaku Co Pyridopyrimidine or naphthyridine derivative.
US20030105115A1 (en) * 2001-06-21 2003-06-05 Metcalf Chester A. Novel pyridopyrimidines and uses thereof
EP1408985A4 (en) * 2001-06-21 2006-03-22 Ariad Pharma Inc Novel pyridopyrimidones and uses thereof
EA007395B3 (en) * 2002-01-22 2018-02-28 Уорнер-Ламберт Компани Ллс 2-(PYRIDINE-2-YLAMINO)PYRIDO[2,3-d]PYRIMIDIN-7-ONES
AU2003225072A1 (en) 2002-04-19 2003-11-03 Smithkline Beecham Corporation Novel compounds
AU2003250701A1 (en) 2002-07-31 2004-02-16 Wayne R. Danter Protein tyrosine kinase inhibitors
DE60318089T2 (en) 2002-10-09 2008-12-04 Critical Outcome Technologies, Inc. PROTEIN TYROSINE KINASE INHIBITORS
DE602004021558D1 (en) * 2003-01-17 2009-07-30 Warner Lambert Co 2-AMINOPYRIDINE SUBSTITUTED HETEROCYCLES AS INHIBITORS OF CELLULAR PROLIFERATION
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
US8362017B2 (en) 2003-08-29 2013-01-29 Exelixis, Inc. C-kit modulators and methods of use
SI1685131T1 (en) 2003-11-13 2007-06-30 Hoffmann La Roche Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
DE102004029784A1 (en) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel 2-Benzylaminodihydropteridinones, process for their preparation and their use as medicaments
DE102004033670A1 (en) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg New pyridodihydropyrazinone, process for its preparation and its use as a medicament
FR2873118B1 (en) 2004-07-15 2007-11-23 Sanofi Synthelabo PYRIDO-PYRIMIDINE DERIVATIVES, THEIR APPLICATION IN THERAPEUTICS
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
EP1630163A1 (en) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinones, methods for their preparation and their use as drugs
CA2575804A1 (en) * 2004-08-26 2006-03-02 Boehringer Ingelheim International Gmbh Pteridinones used as plk (polo like kinase) inhibitors
DE102004058337A1 (en) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for the preparation of fused piperazin-2-one derivatives
US7652041B2 (en) 2005-01-14 2010-01-26 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with kinase inhibitory activity
PE20100741A1 (en) 2005-03-25 2010-11-25 Glaxo Group Ltd COMPOUNDS DERIVED FROM 3,4-DIHYDROPYRIMIDE [4,5-d] PYRIMIDIN-2 (1H) -ONE AS KINASE INHIBITORS p38
AR053346A1 (en) 2005-03-25 2007-05-02 Glaxo Group Ltd COMPOSITE DERIVED FROM 8H -PIRIDO (2,3-D) PIRIMIDIN -7 ONA 2,4,8- TRISUSTITUTED PHARMACEUTICAL COMPOSITION AND USE TO PREPARE A COMPOSITION FOR TREATMENT AND PROFILXIS OF A DISEASE MEDIATED BY KINASE CSBP / RK / P38
JP2008535822A (en) 2005-03-25 2008-09-04 グラクソ グループ リミテッド New compounds
WO2006104917A2 (en) 2005-03-25 2006-10-05 Glaxo Group Limited Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1h)-one derivatives
US7737155B2 (en) * 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
FR2887882B1 (en) * 2005-07-01 2007-09-07 Sanofi Aventis Sa PYRIDO [2,3-D] PYRIMIDINE DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION
US7642270B2 (en) 2005-09-14 2010-01-05 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
TW200800983A (en) 2005-09-14 2008-01-01 Janssen Pharmaceutica Nv 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
PL1940839T3 (en) * 2005-10-07 2013-12-31 Exelixis Inc PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kalpha
EP1931670B1 (en) 2005-10-07 2012-09-12 Exelixis, Inc. Pyridopyrimidinone inhibitors of pi3k
FR2896246B1 (en) 2006-01-13 2008-08-15 Sanofi Aventis Sa PYRIDO-PYRIMIDONE DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
AP2710A (en) 2006-09-15 2013-07-30 Pfizer Prod Inc Pyrido (2, 3-D) Pyrimidinone compounds and their use as P13 inhibitors
BRPI0715566A2 (en) * 2006-10-16 2013-07-02 Gpc Biotech Inc compound, prodrug, pharmaceutical composition, use of a compound, method for inhibiting cell proliferation and method for synthesizing a compound
EP1914234A1 (en) 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
US20080114007A1 (en) * 2006-10-31 2008-05-15 Player Mark R 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase
FR2910813B1 (en) 2006-12-28 2009-02-06 Sanofi Aventis Sa NEW THERAPEUTIC USE FOR THE TREATMENT OF LEUKEMIA
DK2137184T3 (en) * 2007-04-03 2013-07-22 Array Biopharma Inc IMIDAZO [1,2-A] PYRIDINE COMPOUNDS AS RECEPTOR-TYROSINKINASE INHIBITORS
RU2010101052A (en) * 2007-06-15 2011-07-20 Банью Фармасьютикал Ко., Лтд (Jp) Bicycloaniline derivatives
EP2185559A1 (en) 2007-08-03 2010-05-19 Boehringer Ingelheim International GmbH Crystalline form of a dihydropteridione derivative
EP2231656A1 (en) 2007-12-19 2010-09-29 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
US8466151B2 (en) 2007-12-26 2013-06-18 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
EP2100894A1 (en) * 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
MX2010010975A (en) * 2008-04-07 2010-11-01 Amgen Inc Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors.
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
CA2999321A1 (en) 2008-07-17 2010-01-21 Critical Outcome Technologies Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
UY32153A (en) 2008-09-30 2011-04-29 Exelixis Inc PY13KA (ALFA) AND MTOR PYRIDOMIDINONE INHIBITORS
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
MX2012004157A (en) * 2009-10-09 2012-08-03 Afraxis Inc 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders.
JP5797664B2 (en) * 2009-12-18 2015-10-21 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイションＴｅｍｐｌｅ Ｕｎｉｖｅｒｓｉｔｙ−Ｏｆ Ｔｈｅ Ｃｏｍｍｏｎｗｅａｌｔｈ Ｓｙｓｔｅｍ Ｏｆ Ｈｉｇｈｅｒ Ｅｄｕｃａｔｉｏｎ Substituted pyrido [2,3-d] pyrimidin-7 (8H) -ones and their therapeutic use
US8901137B2 (en) 2010-02-09 2014-12-02 Exelixis, Inc. Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors
CA2999435A1 (en) 2010-04-01 2011-10-06 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
DK2600719T3 (en) 2010-08-05 2014-12-15 Univ Temple 2-Substituted 8-alkyl-7-oxo-7,8-dihydropyrido [2,3-d] pyrimidine-6-carbon nitriles and uses thereof
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9133224B2 (en) 2010-11-29 2015-09-15 OSI Pharmaceuticals, LLC Macrocyclic kinase inhibitors
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
DK2937349T3 (en) 2011-03-23 2017-02-20 Amgen Inc CONDENSED TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
MX347040B (en) * 2011-05-17 2017-04-10 Principia Biopharma Inc Tyrosine kinase inhibitors.
WO2013126656A1 (en) * 2012-02-23 2013-08-29 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
ES2694787T3 (en) * 2013-02-21 2018-12-27 Pfizer Inc. Solid forms of a selective CDK4 / 6 inhibitor
EP3024464A1 (en) 2013-07-26 2016-06-01 Boehringer Ingelheim International GmbH Treatment of myelodysplastic syndrome
JP6631616B2 (en) * 2014-07-26 2020-01-15 ノース・アンド・サウス・ブラザー・ファーマシー・インベストメント・カンパニー・リミテッド 2-Amino-pyrido [2,3-d] pyrimidin-7 (8H) -one derivatives as CDK inhibitors and uses thereof
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
TWI646094B (en) * 2016-06-01 2019-01-01 大陸商貝達藥業股份有限公司 Crystal form of inhibitory protein kinase active compound and application thereof
RU2726115C1 (en) 2016-08-15 2020-07-09 Пфайзер Инк. Pyridopyrimidine inhibitors cdk2/4/6
US11192890B2 (en) * 2017-03-03 2021-12-07 Auckland Uniservices Limited FGFR kinase inhibitors and pharmaceutical uses
SG11202007754UA (en) 2018-02-15 2020-09-29 Nuvation Bio Inc Heterocyclic compounds as kinase inhibitors
CN113166148B (en) * 2018-12-07 2024-04-12 杭州英创医药科技有限公司 Heterocyclic compounds as CDK-HDAC dual pathway inhibitors
CN112759589B (en) * 2019-11-01 2022-04-08 暨南大学 Pyrimidopyridinones and their use
CN114901659A (en) 2019-11-26 2022-08-12 施万生物制药研发Ip有限责任公司 Fused pyrimidinone compounds as JAK inhibitors
JP2024508901A (en) * 2021-03-08 2024-02-28 曁南大学 Pyridopyrimidine compounds and their uses
WO2024056091A1 (en) * 2022-09-16 2024-03-21 华东师范大学 Pyridonopyrimidine derivative as rsk inhibitor and use thereof
WO2024099403A1 (en) * 2022-11-10 2024-05-16 北京普祺医药科技股份有限公司 Thioether compound having soft drug property and use thereof, and pharmaceutical composition and use thereof
WO2024107730A1 (en) * 2022-11-14 2024-05-23 Onconova Therapeutics, Inc. Methods and compositions for treating cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
WO1998033798A2 (en) * 1997-02-05 1998-08-06 Warner Lambert Company Pyrido[2,3-d]pyrimidines and 4-amino-pyrimidines as inhibitors of cell proliferation
AP2000001964A0 (en) * 1998-05-26 2000-12-31 Warner Lambert Co Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation.

Also Published As

Publication number Publication date
NO20024235L (en) 2002-11-05
TNSN01036A1 (en) 2005-11-10
CR6736A (en) 2004-03-10
BR0109056A (en) 2003-06-03
YU66502A (en) 2005-09-19
HUP0300136A2 (en) 2003-05-28
JP2003528101A (en) 2003-09-24
OA12227A (en) 2004-03-18
ZA200207110B (en) 2003-12-04
KR20020075805A (en) 2002-10-05
AR034119A1 (en) 2004-02-04
IS6524A (en) 2002-08-23
EP1268476A1 (en) 2003-01-02
SK12472002A3 (en) 2003-04-01
EE200200506A (en) 2004-02-16
HN2001000040A (en) 2001-09-06
AU2001233028A1 (en) 2001-10-03
NZ520962A (en) 2003-09-26
CN1422268A (en) 2003-06-04
MA26881A1 (en) 2004-12-20
SV2001000338A (en) 2001-11-30
CZ20022929A3 (en) 2003-02-12
CO5280200A1 (en) 2003-05-30
IL151480A0 (en) 2003-04-10
AP2002002643A0 (en) 2002-12-31
HRP20020798A2 (en) 2004-02-29
DZ3308A1 (en) 2001-09-27
NO20024235D0 (en) 2002-09-05
WO2001070741A1 (en) 2001-09-27
EA200200802A1 (en) 2003-02-27
PA8513201A1 (en) 2003-06-30
PL358271A1 (en) 2004-08-09
GT200100037A (en) 2002-03-04
CA2401368A1 (en) 2001-09-27
MXPA02008535A (en) 2002-12-13
PE20011177A1 (en) 2001-11-23

Similar Documents

Publication Publication Date Title
BG107161A (en) 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors
GEP20063915B (en) PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS AND USE THEREOF FOR TREATING p38 KINASE-ASSOCIATED CONDITIONS
TR200102001T2 (en) Pyrazoles substituted as P38 kinase inhibitors
YU50402A (en) Pyrido(2,3-d)pyrimidine-2,7-diamine kinase inhibitors
NO308108B1 (en) Pyrrolo [2,3-d] pyrimidines and their use in the manufacture of a drug
YU73300A (en) Bicyclic pyrimidines and bicyclic 3,4-dihydro-pyrimidines as inhibitors of cellular proliferation
BG104949A (en) Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction
UY27198A1 (en) NEW BENCIMIDAZOL ANTI-INFLAMMATORY COMPOUNDS
BG107960A (en) Ether derivatives useful as inhibitors of pde4 isozymes
PE20020305A1 (en) 2- (4-PYRIDYL) AMINO-6-DIALCOXYPHENYL-PYRIDO [2,3-d] PYRIMIDIN-7-ONAS AS INHIBITORS OF TYROSINE KINASE
NZ591712A (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
NO20000702L (en) cGMP PDE inhibitors for the treatment of erectile dysfunction
NZ533310A (en) Benzimidazoles useful as protein kinase inhibitors
NZ517758A (en) Pyrazolopyrimidines useful as therapeutic agents
MXPA02007981A (en) Substituted beta carbolines with ikb kinase inhibiting activity.
BG105346A (en) Pyrolopyrimidines as protein kinase inhibitors
DE60024854D1 (en) 4,5-DISUBSTITUTED 2-AMINOPYRIMIDINE
TW200744604A (en) P38 MAP kinase inhibitors and methods for using the same
NZ333706A (en) Benzenesulfone derivatives and medicaments
MY110191A (en) 1,2,4-oxadiazolyl-phenoxyalkylisoxazoles and their use as antiviral agents
HUP0303034A2 (en) Novel 7-azaindole-derivatives, use thereof as phosphodiesterase 4 inhibitors and method for producing the same
PL1758860T3 (en) Saturated and unsaturated 3-pyridyl-benzocycloalkylmethyl-amines for use in the treatment of pains, depressions and anxiety states
ATE353651T1 (en) 3-FURYLAN ALOGS OF TOXOFLAVIN AS KINASE INHIBITORS
MXPA04000065A (en) Aryl (or heteroaryl) azolylcarbynol derivatives for the treatment of urinary incontinence.
UA87895C2 (en) Substituted 5-phenyl pyrimidines i in therapy